Clear-cell Metastatic Renal Cell Carcinoma Clinical Trial
Official title:
A Comparison of Blood and Tissue Biomarkers Before and After Nephrectomy in the First-line Setting With Everolimus in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Disease and Stage: Metastatic and locally advanced clear cell renal carcinoma
An open-label, exploratory, single-arm, multicenter trial.
Everolimus will be administered orally, once daily, for 6 weeks followed by a 1-week rest
period prior to nephrectomy.
Two to four weeks after surgery, everolimus will be reintroduced only for metastatic
patients until disease progression, unacceptable toxicity, withdrawal of patient consent, or
other stopping rules are met.
An open-label, exploratory, single-arm, multicenter trial. Treatment with everolimus will be
initiated once patients have undergone baseline screening and provided their written
informed consent.
Everolimus will be administered orally, once daily, for 6 weeks followed by a 1-week rest
period prior to surgery. The starting dose will be 10 mg daily with provision for dose
reduction based on tolerability.
Radical nephrectomy will be performed at the end of week 7. For metastatic patients, two to
four weeks after surgery, everolimus will be reintroduced. Treatment will be continued until
disease progression, unacceptable toxicity, withdrawal of patient consent, or other stopping
rules are met.
Patients with locally advanced renal carcinoma will stop drug intake before nephrectomy.
Resumption of everolimus may be postponed in cases of a delay in wound healing or surgical
complications.
After treatment discontinuation and the last treatment visit (28-days after the last dose),
patients will be followed up in order to collect data on the onset of progression and
survival. In metastatic patients discontinuing treatment for reasons other than disease
progression, tumor assessment will continue every 3 months, until disease progression or
initiation of other anticancer therapy for up to one year of follow-up.
;
Intervention Model: Single Group Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05567588 -
Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02880943 -
Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)
|
Phase 1/Phase 2 | |
Completed |
NCT02917772 -
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT01693822 -
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
|
Phase 2 | |
Terminated |
NCT02535351 -
Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
|
Phase 3 | |
Terminated |
NCT02386111 -
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
Not yet recruiting |
NCT06279403 -
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02724020 -
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT02978404 -
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
|
Phase 2 | |
Completed |
NCT01521715 -
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
|
Phase 4 | |
Recruiting |
NCT05263050 -
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01472081 -
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
|
Phase 1 | |
Completed |
NCT05745142 -
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
|
||
Completed |
NCT02228954 -
IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC)
|
||
Terminated |
NCT02570789 -
Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy
|
Phase 4 |